|Bid||2.33 x 2500|
|Ask||3.99 x 300|
|Day's range||2.52 - 2.62|
|52-week range||2.02 - 5.70|
|PE ratio (TTM)||N/A|
|Earnings date||2 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.90|
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
The gene-sequencing company didn't have much good news from the fourth quarter, but better days could be ahead.
The Menlo Park, California-based company said it had a loss of 18 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Pacific Biosciences (PACB) needs investors to pay close attention to the stock based on moves in the options market lately.
Another big purchase order for the genome sequencing equipment manufacturer ahead of its full-year 2017 earnings report is just what investors wanted to see.
MENLO PARK, California and SHENZHEN, China, Jan. 25, 2018 (GLOBE NEWSWIRE) -- BGI, one of the world’s largest genomics organizations, and Pacific Biosciences of California, Inc. (Nasdaq: PACB), the leader in long-read sequencing, today announced an agreement by BGI Genomics to purchase an additional 10 Sequel® Systems. This will significantly expand the capacity for Single Molecule, Real-Time (SMRT®) Sequencing for BGI’s global sequencing service business, which currently operates two Sequel Systems and a PacBio® RS II Sequencing System.
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Despite some bright points, a revenue miss and contracting margins in the company's third-quarter report are taking a toll.
The genetic-sequencing company's higher system sales aren't enough to offset the loss of contract revenue from Roche.
Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.
On a per-share basis, the Menlo Park, California-based company said it had a loss of 19 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.